Informationen und Ansprechpartner zu Ruxo-BEAT
| Studienzentrum | Universitätstumorzentrum UTZ
Klinik für Hämatologie, Onkologie und Klinische Immunologie
Moorenstr. 5
40225 Düsseldorf |
| Kommissarischer Direktor | Herr Prof. Dr. med. Ulrich Germing
|
| Ansprechpartner | Thi Nguyen, Studienassistentin
Tel: 0211 81-17714
Thi.Nguyen@med.uni-duesseldorf.de
|
| Studienbeschreibung |
| 12-181 (MPN) | Ruxo-BEAT |
| Studientitel | The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk
Essential Thrombocythemia (Ruxo-BEAT)
|
| Kurzbeschreibung | The Philadelphia chromosome negative myeloproliferative neoplasms (MPN)
comprise a group of clonal hematological malignancies that are characterized by
chronic myeloproliferation, splenomegaly, different degrees of bone marrow
fibrosis, and disease-related symptoms including pruritus, night sweats, fever,
weight loss, cachexia, and diarrhea. In addition, due to elevated numbers of
leucocytes, erythrocytes and/or platelets, the disease course can be complicated
by thromboembolic disease, hemorrhage, and leukemic transformation as well as
myelofibrosis.
Patients with polycythemia vera (PV) typically harbor an increased number of
blood cells from all three hematopoietic cell lineages due to clonal amplification of
hematopoetic stem cells, while patients with essential thrombocythemia (ET)
typically show a predominant expansion of the megakaryocytic lineage. Most
patients with PV below the age of 60 years are currently being treated with
acetylsalicylic acid +/- phlebotomy only, and patients with low-risk ET have an
almost normal life expectancy and often do not require specific treatment.
However, PV- as well as ET-patients with a higher risk for complications require
cytoreductive treatment. In addition, constitutional symptoms can be unbearable
to patients even in the absence of bona fide high risk factors, and these patients
may similarly benefit from antineoplastic therapy.
|
| Betreffendes Organsystem | Leukämien/Lymphome
(Hodgkin-Lymphom, Non-Hodgkin-Lymphom, Akute Leukämie, Chronische Leukämie, Multiples Myelom/Plasmozytom, Myelodysplastisches Syndrom, Myeloproliferatives Syndrom) |
| Gesamte Studienbeschreibung | https://clinicaltrials.gov/show/NCT02577926 |
| Studientyp | Therapie-Studie |
| Studienstatus | Rekrutierung offen (Teilnehmer werden aufgenommen) |
Für weitere Informationen - auch zu den Ein-/Auschlusskriterien - wenden Sie sich bitte an die oben genannten Ansprechpartner im Studienzentrum.
